You are here
The T-cell immunotherapies market
The T-cell immunotherapies market is projected to reach USD 26 Billion by 2030, growing at an annualized rate of 41.5%, claims Roots Analysis
Roots Analysis has announced the addition of “Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030” report to its list of offerings.
Key Market Insights
Close to 650+ candidate therapies in the development pipeline
CAR-T cell products continue to dominate the clinical / preclinical pipeline, representing 75% of the total number of molecules, followed by TCR (18%) and TIL (7%) based therapies. It is worth highlighting that 63% of pipeline therapies are presently in the clinical stage. Examples of late-stage clinical candidates include bb2121 (bluebird bio and Celgene), JCAR017 (Celgene, Juno Therapeutics and WuXi AppTec), GSK3377794 (GlaxoSmithKline, Adaptimmune Therapeutics and Merck), IMCgp100 (Immunocore and MedImmune) and Lifileucel (Iovance Biotherapeutics).
Currently, the focus is on hematological malignancies and solid tumor indications
More than 85% of the products in the development pipeline are presently being developed to treat various types of cancers, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma and melanoma. Only 3% of pipeline candidates are being evaluated for the treatment of non-oncological indications.
Extensive efforts are underway to improve the CAR constructs
Majority of the CAR-T cell therapies in the clinical development, including the two recently approved products, are based on second generation CARs. Further, lentivirus and retrovirus are presently the preferred type of vectors used for CARs transduction into T-cells.
China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
In the last 10 years, over 410 clinical trials, evaluating various types of CAR-T cell therapies, were registered across different geographies; interestingly, over 50% of these trials are being conducted in China.
Over to USD 13.8 billion invested by both private and public investors, since 2012
Around USD 4.4 billion was raised through venture capital financing, representing around 37% of the total capital raised by industry players in the given time period (till May 2019). Further, in the last five years, there have been 18 IPOs accounting for more than 2.4 billion in financing of T-cell therapy related initiatives.
280+ partnerships established between 2012 and 2019
The partnership activity in this domain has increased at a CAGR of over 30%. In fact, around 70% of the deals were established post 2015, with the maximum activity being reported in 2018. Majority of the abovementioned agreements were observed to be focused on research and development of T-cell therapies.
North America and Europe anticipated to capture over 85% of market share by 2030
With a promising development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 40% during the next decade. In addition to North American and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.
To request a sample copy / brochure of this report, please visit this link
For additional details, please visit
or email firstname.lastname@example.org
+1 (415) 800 3415
+44 (122) 391 1091
Street name: A430, 4th Floor, Bestech Business Towers, Sector 66,
Pin Code: 60059
About Roots Analysis
We provide market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis covering the following parameters:
- Technology evolution
- Research and development
- Existing market landscape
- Future Commercial potential
- Regulatory concerns
- Regional growth drivers
- Risks and opportunities
We specialise in analysing areas which have lacked quality research so far or require more focussed understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.